Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.
Term
Q3 2026
“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”
Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.
Atossa Therapeutics declared a dividend of one stapled contingent value right (CVR) for each share of common stock to participate in the potential future monetization of a priority review voucher. The CVRs entitle holders to 25% of the net proceeds from the sale or monetization of the first qualifying FDA priority review voucher awarded to the company, subject to an aggregate payment cap of $50 million. The rights are currently stapled to the common stock and expire on December 31, 2036, if no voucher is awarded.
Atossa Therapeutics announced a plan to issue one contingent value right (CVR) for each share of common stock, allowing shareholders to receive 25% of net proceeds from the potential monetization of its first qualifying FDA rare pediatric disease priority review voucher. The CVR payments are subject to an aggregate cap of $50 million and are tied to the company's (Z)-endoxifen development programs. The CVRs will be 'stapled' to the common stock and will not trade separately.
Atossa Therapeutics made available an updated corporate and investor presentation on September 18, 2026, highlighting its clinical development strategy for (Z)-Endoxifen. The presentation covers the company's oncology core and rare disease expansion, including Phase 2 progress in breast cancer and regulatory designations for McCune-Albright Syndrome and Duchenne Muscular Dystrophy.